Rebiotix Inc., a Ferring Company, is working closely with the U.S. FDA as it conducts an advanced clinical research program

Clinical Trials

Rebiotix Inc., a Ferring Company, has conducted several clinical trials with it’s lead microbiota-based product in the MRT™ drug platform, RBX2660 for the prevention of recurrent Clostridium difficile (C. diff) infection, and is currently enrolling in a Phase 3 clinical trial, in conjunction with the U.S Food and Drug Administration under an Independent New Drug Application.

For currently enrolling clinical trials, go to clinicaltrials.gov.

Important milestones include:

PUNCH CD study: Phase 2 multicenter, open-label study. Reported in October 2014.
PUNCH CD 2: Phase 2B, prospective, multi-center randomized double-blind, placebo-controlled study of a microbiota-based drug. Results reported Q4 2016.
PUNCH Open Label: Phase 2 prospective, multi-center, open label controlled trial. Topline results reported April 2017.
Phase 3 PUNCH CD 3 – completes enrollment (click for details). Initiated Q3 2017.
Acquired by Ferring Pharmaceuticals in April 2018.
Rebiotix Announces World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660. Preliminary results reported May 2020.
PUNCH CD3-OLS – currently enrolling (click for details). Initiated March 2020.

Special FDA designations for RBX2660:

Fast Track – May 2013
Orphan Drug – March 2014
Breakthrough Therapy – October 2015